ABAI-30 is a potent and orally active anti-inflammatory agent. ABAI-30 effectively inhibits NO production in lipopolysaccharide (LPS) induced RAW264.7 cells^[1].

In RAW264.7 cells, ABAI-30 (10-40 μM) inhibits the TLR4-pp65 and NLRP3-caspase-1 signaling pathway, thus leading to the downregulation of IL6, IL-1β and TNFα at both transcriptional and translational levels^[1].

In a dextran sulfate sodium (DSS)-induced colitis mouse model, ABAI-30 (25 mg/kg; oral administration; for 5 days) demonstrates high in vivo anti-inflammatory efficacy without causing obvious toxicity^[1].

347.33

C₁₇H₁₃N₇O₂

2757957-25-6

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.